Twist Bioscience (NASDAQ:TWST) Stock: Insider Dennis Cho Sells 949 Shares

Twist Bioscience Corporation (NASDAQ:TWST) insider Dennis Cho sold 949 shares of the firm’s stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total value of $128,494.60. Following the transaction, the insider owned 62,840 shares in the company, valued at approximately $8,508,536. This trade represents a 1.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dennis Cho also recently made the following trade(s):

• On Friday, October 2nd, Dennis Cho sold 9,514 shares of Twist Bioscience stock. The stock was sold at an average price of $188.88, for a total transaction of $1,797,004.32.
• On Monday, September 21st, Dennis Cho sold 348 shares of Twist Bioscience stock. The shares were sold at an average price of $165.49, for a total transaction of $57,590.52.
• On Tuesday, September 8th, Dennis Cho sold 412 shares of Twist Bioscience stock. The shares were sold at an average price of $122.62, for a total transaction of $50,519.44.

Twist Bioscience Trading Up 0.1%

Twist Bioscience stock opened at $120.79 on Friday. The stock has a market cap of $7.57 billion, a P/E ratio of -54.41 and a beta of 2.25. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $219.71. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The company’s fifty day simple moving average is $151.35 and its 200-day simple moving average is $91.08.

Institutional Investors Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of the business. Private Advisory Group LLC bought a new stake in Twist Bioscience in the third quarter worth $1,533,000. Russell Investments Group Ltd. grew its position in shares of Twist Bioscience by 190.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 283,910 shares of the company’s stock valued at $54,863,000 after buying an additional 186,294 shares during the last quarter. Pier 88 Investment Partners LLC acquired a new stake in Twist Bioscience in the 3rd quarter valued at approximately $676,000. Lisanti Capital Growth LLC bought a new position in Twist Bioscience during the 3rd quarter worth approximately $5,584,000. Finally, Ritholtz Wealth Management bought a new position in shares of Twist Bioscience during the third quarter worth approximately $327,000.

Key Headlines Impacting Twist Bioscience

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist launched MRD Express, potentially expanding its presence in minimal residual disease testing. Investors may look for further details on the product and business outlook around earnings. Article: Twist Bioscience stock enters earnings week after MRD Express launch
• Neutral Sentiment: CEO Emily Leproust and three other insiders sold a combined 6,677 shares at $135.40. The sales were disclosed as covering tax withholding on equity-award vesting, and each seller retained a substantial stake.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The provided article headline does not specify the report’s allegations, but its release appears to have hurt sentiment. Article: Twist Bioscience falls amid negative report

Analyst Upgrades and Downgrades

TWST has been the subject of several research reports. Guggenheim upped their price objective on shares of Twist Bioscience from $107.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Barclays raised their target price on shares of Twist Bioscience from $112.00 to $215.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Leerink Partners raised their target price on Twist Bioscience from $160.00 to $190.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 29th. Jefferies Financial Group started coverage on shares of Twist Bioscience in a research note on Thursday, October 8th. They issued a “hold” rating and a $150.00 price objective for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Monday, September 21st. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $153.00.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.